Funding Type: Investments

VenomAid — Rapid Diagnostics for Snakebites

Open Philanthropy recommended an investment of $487,356 in VenomAid, a Danish company commercializing inexpensive rapid diagnostics for many different species of venomous snakes.

If clinics can rapidly identify which snake species caused a given snakebite, they can quickly administer the correct antivenom, which we believe will substantially lower snakebite morbidity and mortality.

This falls within our focus area of scientific research, specifically within our interest in advancing human health and wellbeing.

Kainomyx — Antimalarial Drug (2021)

Open Philanthropy recommended an investment of $4,000,000 in Kainomyx to develop and produce new drugs to treat malaria and other parasitic diseases, such as cryptosporidiosis and toxoplasmosis. If effective, the new drugs would act by inhibiting cytoskeletal proteins in malarial and other parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing resistance to existing treatments.

This follows our May 2020 investment and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

OliLux Biosciences — Rapid Tuberculosis Detection and Treatment Management Tools

Grant investigators: Heather Youngs and Chris Somerville

This page was reviewed but not written by the grant investigators. OliLux Biosciences staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $400,000 in OliLux Biosciences to support the development of diagnostic and treatment monitoring tools for the detection and management of tuberculosis. The tools rapidly distinguish between active and inactive tuberculosis pathogens, have lower detection limits than existing detection methods, will be accessible in low-resource settings, and are expected to be useful in identification of drug resistance and sensitivity.

This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

VasoRX — Atherosclerosis and Pulmonary Arterial Hypertension Therapy

Grant investigators: Heather Youngs and Chris Somerville

This page was reviewed but not written by the grant investigators. VasoRX staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $5,550,000 in VasoRX to continue work testing a new therapy for vascular diseases such as atherosclerosis and pulmonary arterial hypertension. This seed-stage investment is intended to support additional research and development in the hopes that VasoRX can subsequently raise additional funds from other investors to conduct a clinical trial of the therapy in humans.

This follows our April 2018 support and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

Binx — COVID-19 Testing Platform

Grant investigators: Heather Youngs and Chris Somerville

This page was reviewed but not written by the grant investigators. Binx staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $2,000,000 in Binx to support work to incorporate Sherlock Biosciences’s COVID-19 assay into Binx’s point-of-care diagnostic platform. This funding is intended to support work to obtain Emergency Use Authorization approval of the Binx-Sherlock Biosciences COVID-19 testing platform.

This falls within our work on scientific research, specifically within our interest in advancing science supporting biosecurity and pandemic preparedness.

Icosavax — COVID-19 Vaccine Development

Grant investigators: Chris Somerville and Heather Youngs

This page was reviewed but not written by the grant investigators. Icosavax staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $6,500,000 in Icosavax to support the development of their virus-like-particle vaccine platform, including a new COVID-19 vaccine. Compared with other vaccines in development, Icosavax’s vaccine may more effectively protect those with weakened immune responses against COVID-19. If the vaccine is found to be effective, our science team believes that the use of of Icosavax’s virus-like-particle technology may be valuable in the development of vaccines for other viral diseases with pandemic potential. Icosavax was founded by Open Philanthropy grantees David Baker and Neil King.

This falls within our work on scientific research, specifically within our interest in science supporting biosecurity and pandemic preparedness.

Riboscience — COVID-19 Drug Research

Grant investigators: Chris Somerville and Heather Youngs

This page was reviewed but not written by the grant investigators. Riboscience staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $210,000 in Riboscience to support work to test a new drug candidate against COVID-19.

This falls within our work on scientific research, specifically within our interest in advancing science supporting biosecurity and pandemic preparedness.

VST Bio — Stroke Treatment

Grant investigators: Chris Somerville and Heather Youngs

This page was reviewed but not written by the grant investigators. VST Bio staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $4,500,000 in VST Bio to develop a novel treatment for stroke and traumatic brain disease. Stroke is the second most common cause of death worldwide and the third most common cause of disability. Currently, there are no drugs that reduce the brain damage caused by acute stroke. Following our March 2019 support to Yale University, researchers developed antibodies that significantly reduce the brain damage caused by stroke in mice. This seed-stage investment is intended to support additional research and development in the hopes that VST Bio can subsequently raise additional funds from other investors to conduct a clinical trial of the treatment in humans.

This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

The investment amount was updated in April 2022.

Kainomyx — Antimalarial Drug (2019)

Grant investigators: Chris Somerville and Heather Youngs

This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.

Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.

This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.